Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors Meeting Abstract
| Authors: | Ribas, A.; Hong, D.; Tolcher, A.; Sullivan, R.; Shapiro, G.; Chmielowski, B.; Brail, L.; Lee, L.; Mahabhashyam, S.; Ullmann, C. D.; Postow, M.; Wolchok, J. |
| Abstract Title: | Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors |
| Meeting Title: | 32nd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 5 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Nov 8-12 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2017-11-07 |
| Start Page: | 87 |
| Language: | English |
| DOI: | 10.1186/s40425-017-0288-4 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: P219 |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work